| 000 | 02745cam a2200313 4500500 | ||
|---|---|---|---|
| 005 | 20250121154508.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aMrowietz, Ulrich _eauthor |
| 700 | 1 | 0 |
_a Sorbe, Christina _eauthor |
| 700 | 1 | 0 |
_a Reich, Kristian _eauthor |
| 700 | 1 | 0 |
_a Von Kiedrowski, Ralph _eauthor |
| 700 | 1 | 0 |
_a Weckbecker, Jörg _eauthor |
| 700 | 1 | 0 |
_a Radtke, Marc A. _eauthor |
| 700 | 1 | 0 |
_a Rustenbach, Stephan J. _eauthor |
| 700 | 1 | 0 |
_a Augustin, Matthias _eauthor |
| 245 | 0 | 0 | _aFumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care |
| 260 | _c2020. | ||
| 500 | _a46 | ||
| 520 | _aBackground: Fumaric acid esters (FAE) represent the most widely-used oral systemic treatment for moderate-to-severe psoriasis in Germany. Not licensed outside Germany, little is known about the demographics of patients receiving FAE. PsoBest is a large national patient registry documenting long-term treatment of psoriasis in Germany. Objectives: To evaluate FAE relative to methotrexate (MTX) in patients from the PsoBest registry. Materials and Methods: Patient demographics, disease severity at baseline and dosing regimen were reported for patients who initiated treatment with either FAE or MTX between 2007 and 2015. Results: Overall, 1,409 patients treated with FAE and 877 with MTX were analysed. At baseline, compared with the MTX cohort, patients receiving FAE were younger (45.4 vs. 50.2 years; p≤0.001) and had a lower BMI (28.0 vs. 28.3 kg/m2; p≤0.023) and less nail involvement (45.4% vs. 50.7%; p≤0.013). The MTX cohort reported a greater mean duration of illness at baseline (18.2 years vs. 14.9 years; p≤0.001). In total, 85.6% and 58.5% patients in the FAE and MTX cohorts, respectively, had not received prior systemic therapy. Cardiovascular disease was the most prevalent comorbidity (FAE: 26.7%; MTX: 31.5%; p≤0.014). Health-related quality of life was similar for both cohorts (mean DLQI: 10.8 [FAE]; 10.5 [MTX]; p≤0.079). Mean FAE dose was 165.0 mg at inclusion and 406.4 mg following up-titration. Conclusion: This study contributes to a better understanding of the usual practices of long-term FAE use, which may also lead to improved treatment strategies not only in Germany, but in other countries where FAE may become available in the near future. | ||
| 690 | _apsoriasis | ||
| 690 | _areal-world data | ||
| 690 | _aPsoBest | ||
| 690 | _afumaric acid esters | ||
| 690 | _apatient characteristics | ||
| 690 | _aregistry | ||
| 786 | 0 | _nEuropean Journal of Dermatology | 30 | 1 | 2020-01-01 | p. 41-48 | 1167-1122 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/revue-european-journal-of-dermatology-2020-1-page-41?lang=en&redirect-ssocas=7080 |
| 999 |
_c602450 _d602450 |
||